Tactile Systems Technology said today it launched its Flexitouch device designed to treat lymphedema of the head and neck, touting it as the 1st and only pneumatic compression therapy approved for the condition.
The Flexitouch device is designed to use pneumatic compression to stimulate the lymphatic system to deliver non-invasive, self-delivered therapy for lymphedema, which is a common result of head and neck cancer and their treatments, the Minneapolis, Minn.-based company said.
“We are thrilled with these positive results demonstrating that the Flexitouch system can help head and neck lymphedema patients effectively reduce lymphedema swelling and improve their quality of life. The Flexitouch system has helped tens of thousands of patients achieve better health and manage lymphedema symptoms in their extremities. Now, for the first time, we can extend the benefits of Flexitouch to every area of the body. We have been encouraged to hear that many patients are able to feel a substantial difference in their condition after just one treatment. With very few treatment options available for these patients, we are extremely gratified that we can now extend the benefits of our Flexitouch system to patients suffering from head and neck lymphedema and help them better manage their condition at home,” CEO Gerald Mattys said in a press release.
Tactile Medical won FDA clearance for the device in September last year, followed by a limited market release to more than 80 patients, 88% of which said they saw a reduction in head and neck swelling after an initial 32-minute treatment.
A total of 89% of the patietns reported improvement in other systems, including swallowing ability, lowered discomfort, range of motion and reduction in fibrotic tissue.